Wednesday, December 22, 2021 2:43:19 PM
Just an observation and an opinion here. Michaels was subtly trying to inform the public that the valuations commanded by companies working in the same area as CUBT are significantly higher than the current market cap.
There is no way to compare apples to apples, because each situation is different.
CUBT could have positive results from the Metformin eye drop trials that raises the company's profile to attract a partner or more.
A PRV for the rabies drug alone could be monetized for over $100 million. No way of knowing if or when. But the potential is there.
Covid vaccine adjunct? Huge possibilities -- and worth nothing in the stock price right now.
Never fun to see tax loss selling hit a stock so hard on so little volume.
I had a GTC order to buy at $0.05 that I really did not think I would get, but I did today.
GLTA--January is coming soon.
Recent CUBT News
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 05/06/2024 09:31:41 PM
Avant Technologies and Ainnova Tech Form Joint Venture to Advance Early Disease Detection Using Artificial Intelligence • AVAI • Nov 12, 2024 9:00 AM
Swifty Global Announces Launch of Swifty Sports IE, Expanding Sports Betting and Casino Services in the Irish Market • DRCR • Nov 12, 2024 9:00 AM
Oohvie App Update Enhances Women's Health with Telemedicine and Online Scheduling • HLYK • Nov 11, 2024 8:00 AM
SANUWAVE Announces Record Quarterly Revenues: Q3 FY2024 Financial Results • SNWV • Nov 8, 2024 7:07 AM
DBG Pays Off $1.3 Million in Convertible Notes, which Retires All of the Company's Convertible Notes • DBGI • Nov 7, 2024 2:16 PM
SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service • SMX • Nov 7, 2024 8:48 AM